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Abstract
Background: Recently, a great effort in microarray data analysis is directed towards the study of the so-called gene
sets. A gene set is defined by genes that are, somehow, functionally related. For example, genes appearing in a
known biological pathway naturally define a gene set. The gene sets are usually identified from a priori biological
knowledge. Nowadays, many bioinformatics resources store such kind of knowledge (see, for example, the Kyoto
Encyclopedia of Genes and Genomes, among others). Although pathways maps carry important information about
the structure of correlation among genes that should not be neglected, the currently available multivariate
methods for gene set analysis do not fully exploit it.
Results: We propose a novel gene set analysis specifically designed for gene sets defined by pathways. Such
analysis, based on graphical models, explicitly incorporates the dependence structure among genes highlighted by
the topology of pathways. The analysis is designed to be used for overall surveillance of changes in a pathway in
different experimental conditions. In fact, under different circumstances, not only the expression of the genes in a
pathway, but also the strength of their relations may change. The methods resulting from the proposal allow both
to test for variations in the strength of the links, and to properly account for heteroschedasticity in the usual tests
for differential expression.
Conclusions: The use of graphical models allows a deeper look at the components of the pathway that can be
tested separately and compared marginally. In this way it is possible to test single components of the pathway
and highlight only those involved in its deregulation.
Background
A microarray experiment typically provides a list of dif-
ferentially expressed genes that represents the starting
point of a highly difficult process of results interpreta-
tion. Biological interpretation becomes easier if differen-
tially expressed genes show some similarity according to
their functional annotation. Thus, in recent years, the
interest has moved from the study of individual genes to
that of groups of genes (defined by functional categories
or metabolic pathways) and methods for gene set analy-
sis have received a great attention. The aim is to identify
groups of genes with moderate, but coordinated, expres-
sion changes, which should enable the understanding of
cellular processes involved in the biological problem at
hand. Such approaches directly score pre-defined gene
sets for differential expression.
Several gene set analysis methods have been recently
developed, both in the univariate and multivariate con-
text. [1] divide gene sets methods into two broad cate-
gories: (i) methods based on enrichment analysis
performed on a list of genes selected through a gene-
level test; (ii) methods based on global and multivariate
approaches that define a model on the whole gene set.
For a comprehensive review on existing methods see [1]
and references therein. For a detailed description and
for a critical investigation of the hypothesis tested in
both approaches see [2-5].
The main concerns with the first class of methods are
the assumption that genes are independent, and the use
of a cut-off threshold value for the selection of differen-
tially expressed genes. Indeed, [6] show that the final
result of these approaches is significantly affected by the
selected threshold, which is normally chosen arbitrarily.
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expression changes are discarded by the strict cut-off
value, which leads to a reduction in statistical power.
On the other hand, global and multivariate approaches
relax the assumption of independence among genes
belonging to the same gene sets and identify moderate,
but coordinated, expression changes that cannot be
detected by the previous approach [3].
In the multivariate perspective, [2] propose Global
Test, modelling differential gene expression by means of
random-effects logistic regression models, while [7] pro-
pose ANCOVA Global Test, which is similar to Global
Test but with phenotype and genes exchanged in regres-
sion models. ANCOVA Global Test seems to outper-
form Global Test, especially in cases where the
asymptotic distribution of Global Test cannot be used
[7]. More recently, [8] propose a MANOVA test using a
shrinkage covariance matrix estimator for the sample
covariance matrix.
One of the databases widely in use for the a priori
definition of gene sets is the Kyoto Encyclopedia of
Genes and Genomes (KEGG in the following) [9], where
gene products are structured into several known meta-
bolic and regulatory pathways. A pathway is a graphical
diagram of biochemical reactions involving different
enzymes, where directed and undirected edges connect
few different gene products at time, according to their
chemical interactions. Although KEGG pathways are
u s u a l l ya p p l i e dt od e f i n eg e n es e t s ,t h ea p p r o a c h e ss o
far proposed do not explicitly take into consideration
the dependence structure among genes implied by the
topology of the pathway.
We propose to pursue the study of the behaviour of
pathways in different experimental conditions within a
graphical models context. This approach, whose applica-
tion in the context of pathways analysis is still largely
unexplored, goes in a direction which can valuably com-
plement approaches more extensively offered by the cur-
rent literature. In fact, by recording the structure of the
pathway in an appropriately defined graph, we are able
to keep track of the biochemical structure and reactions
of the enzymes. In taking this route, the main interest is
not on the detection of the structure of the pathway,
because we consider it as fixed from the very beginning.
In this sense, our approach differs from approaches for
the analysis of differential coexpression [10]. In other
words, we are not interested in learning the structure of
the pathways from the data (see [11]); instead, we
exploit the available biological knowledge to define
appropriate statistical analyses.
Within the graphical models context, data are consid-
ered as coming from Gaussian multivariate distributions
with a structured concentration matrix (inverse of the
covariance matrix), which reflects dependencies among
variables. We present in detail two statistical tests for
comparing gene sets under different experimental condi-
tions, which naturally stem from the adopted theoretical
framework. The first one addresses the question of test-
ing whether the strength of the connections among
genes is altered in different experimental condition. It is
likely to figure that a pathological condition does not
change the structure of a pathway, but, rather, can influ-
ence the strength of the biochemical reactions. For
example, a strong partial correlation among two genes
in the healthy state could diminish in the disease state,
or vice versa. Therefore, discovering any statistically sig-
nificant difference among conditions that share the
same underlying chemical structure is a crucial informa-
tion. Our first test focusses, in particular, on the
strength of the links among gene products and on their
possible changes when considering two (or more)
experimental conditions of interest. The second test is
more traditionally designed for testing for differential
expression. In doing the test, we specifically employ the
information about the behaviour of the partial correla-
tions among genes and about their possible heterosche-
dasticity in different experimental conditions. We stress
that the two tests can be performed independently one
from each other. Of course, if one performs both of
them, there is a suggested natural order, but the particu-
lar research question will define if they are both neces-
sary or if, in a preliminary phase, only one of them is
requested.
The adoption of graphical methods makes it possible
to decompose the overall statistical model into smaller
models, with the aim of exploring in more detail small
portions of the entire model. This ability naturally leads
us to wish to compare portions of the pathways, with
the aim of identifying subgroups of genes which appear
to drive differences (deregulations) of the entire struc-
ture. The application of this idea to biological pathways
is highly innovative, as it allows to look in detail to
components of the pathway, opportunely defined, that
can be studied separately. In fact, the expression/corre-
lation behaviour of a large pathway could be misleading,
hiding significant parts of the pathway mostly involved
in the biological process under exam. With the help of
the graphical models arguments, we attempt to uncover
such parts.
Results and Discussion
Two separate datasets have been used to test our model-
based approach, both pertaining to gene expression
changes derived by specific genetic alterations in cancer.
Data: BCR signaling pathway
The first dataset that we use has been recently published
by [12], and characterizes gene expression signatures in
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Page 2 of 15acute lymphocytic leukemia (ALL) cells associated with
known genotypic abnormalities in adult patients. Several
distinct genetic mechanisms lead to acute lymphocytic
leukemia (ALL) malignant transformations deriving
from distinct lymphoid precursor cells that have been
committed to either T-lineage or B-lineage differentia-
tion. Chromosome translocations and molecular rear-
rangements are common events in B-lineage ALL and
reflect distinct mechanisms of transformation. The rela-
tive frequencies of specific molecular rearrangements
differ in children and adults with B-lineage ALL. The B
cell Receptor (BCR/ABL) gene rearrangement occurs in
about 25% of cases in adult ALL, and much less fre-
quently in pediatric ALL. Because these cytogenetic
abnormalities reflect distinct mechanisms of transforma-
tion, molecular differences between these two types of
rearrangements could help to explain why children and
adults with ALL have such different outcomes following
conventional therapy. Data are freely available at the
Bioconductor web site. Expression values, appropriately
normalized according to rma and quantile normaliza-
tion, derived from Affymetrix single channel technology,
consist of 37 observations from one experimental condi-
tion (n1 = 37, BCR; presence of BCR/ABL gene
rearrangement) and 41 observations from another
experimental condition (n2 = 41, NEG; absence of rear-
rangement). Gene BCR is central in this study, because
it is involved in the process of rearrangement. For this
reason, we decide to focus our approach on the B cell
receptor signaling pathway (represented in Figure 1),
which has the gene BCR as input. If there is a rearran-
gement of this gene, we expect that also the genes
belonging to the connected pathway will be highly influ-
enced from the BCR/ABL gene rearrangement. We con-
sider the whole pathway, that has 35 gene products (p =
35). If one enzyme includes multiple gene products, we
consider as representative of the enzyme the gene most
differentially expressed between the two conditions,
according to SAM test [13].
Data: ERBB signaling pathway
The second dataset published by [14] uses gene expression
profiles of 90 patients affected by lung adenocarcinoma to
determine the relationship between expression and under-
lying genetic changes, which are known to be important
for the pathogenesis of lung cancers. In particular, the
Authors investigate three major targets for genetic
changes, p53, epidermal growth factor receptor (EGFR,
Figure 1 BCR signaling pathway. B cell receptor signaling pathway in human taken from KEGG [9].
Massa et al. BMC Systems Biology 2010, 4:121
http://www.biomedcentral.com/1752-0509/4/121
Page 3 of 15alias ERBB-1), and K-ras. In particular, EGFR mutations
are present in a subset of pulmonary adenocarcinomas,
and tumors with this mutation have been shown to be
highly sensitive to gefitinib, a drug that inhibits EGFR,
selectively targeting proteins in malignant cells. Thus, here
we evaluate the difference between patients with (n1 =3 2 )
and without (n2 = 58) EGFR mutation focusing on ERBB
signaling pathway (reported in Figure 2).
The Authors used a two-channel technology (patients
vs. common reference) with a custom Agilent oligonu-
cleotide microarray, containing a total of 21,619 spots
corresponding to 18,175 unique genes. Data are freely
available at GEO database with GSE11969 ID. For our
analyses we use normalized expression values submitted
in the database. ERBB signaling pathway contains ERBB-
1 (EGFR), ERBB-2, ERBB-3 and ERBB-4 enzymes and
their homo- and etero-dimers; unfortunately the oligo-
nucleotide array does not contain spots for ERBB-2.
Thus, we decide to analyze only a part of the pathway
containing 29 gene products. In case of an enzyme con-
taining multiple genes, we follow the strategy described
in the previous paragraph.
Pathways conversion
The pathway is converted into a graphical model follow-
ing the steps described in the Methods section. Firstly,
it is converted into a directed acyclic graph (DAG) D.
For the BCR signaling pathway, for example, the DAG is
s h o w ni nF i g u r e3 .S t a r t i n gf r o mD, we derive its moral
graph D
m. An example of a moralization of a DAG is
g i v e ni nF i g u r e4 .T h em o r a lg r a p hc o r r e s p o n d i n gt o
the DAG in Figure 3 is shown in Figure 5. In the follow-
ing, we denote the undirected graph D
m with G.W e
assume to model the data in the two experimental con-
ditions with two graphical Gaussian models [15] with
the same undirected graph G,

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respectively, with p equal to the number of genes
(vertices of the graph), see Methods for more details. All
the analyses have been performed using R statistical
software, with packages ‘gRbase’ for manipulation of
Figure 2 ERBB signaling pathway. ERBB signaling pathway in human taken from KEGG [9].
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Page 4 of 15graphs, ‘qpgraph’ for the IPS algorithm, ‘samr’ for the
SAM test. All the R scripts are available upon request.
Results
We are interested in (i) comparing the strength of the
links between genes in two experimental conditions; (ii)
testing the differential expression of the pathway. In a
graphical Gaussian models context, (i) is simply
achieved by comparing the two concentration matrices
(inverse of the covariance matrices), because they con-
tain all the information about the underlying structure
of conditional independences among variables. There-
fore, the null hypothesis to be tested is H01
1
2
1 : ΣΣ
−− = ,
which, of course, is equivalent to the hypothesis Σ1 = Σ2.
Testing the differential expression of the pathway is
achieved by checking equality of means, i.e, by testing
H0 : μ1 = μ2. Such test has a different structure accord-
ing to whether the two graphical Gaussian models ℳ1(G)
and ℳ2(G) are homoschedastic, i.e. they have the same
covariance matrix, or not. Therefore, testing the differ-
ential expression of the pathway requires to prelimina-
rily take a decision on equality of the two concentration
matrices. All technical details are derived in Methods.
BCR signaling pathway
The test in (1) rejects the null hypothesis (p-value =
0.003) for the graph shown in Figure 5; this means that
the strength of the connections among genes in this
pathway is significantly different in the BCR/ABL posi-
tive and BCR/ABL negative samples. This result seems
to support our conjecture that in different experimental
conditions the degree of connection among pathway
nodes can change. Taking into account the non-homo-
geneity of the covariances in the two experimental con-
ditions, we can now properly perform the test on the
means reported in (2), rejecting the null hypothesis
(p-value = 0.0001). Even if not directly comparable, this
last result is in agreement with the results derived from
application of the multivariate approaches of [2]
(p-value = 0.0008) and of [8] (p-value < 0.0001).
Thus, patients with BCR rearrangement show a signif-
icant deregulation of the entire pathway centered on the
BCR gene products with respect to those without rear-
rangement. BCR pathway is composed by 35 enzymes
and is characterized by three ways in and four ways out.
As shown before, a classical multivariate approach per-
mits to identify the whole pathway as significantly
involved in the pathology. Nevertheless, it is not able to
d i s c o v e rt h ep r e s e n c eo fp o s sible preferential signals
within the pathway. The use of graphical models in the
context of gene sets analysis allows the decomposition
of the moral (or, if necessary, triangulated) graph into
cliques (see Methods). When tested separately, such
decomposition could highlight those signals that, within
the pathway, are mostly involved in its deregulation.
Since the graph D
m is not decomposable, we consider
a possible triangulated graph. An example of triangula-
tion of a graph is shown in Figure 4. The graph D
t cor-
responding to our pathway is shown in Figure 6, and it
has five added edges and three more cliques in compari-
son with D
m. In particular, the graph D
t has 30 cliques,
whose composition is reported in Table 1. In the same
table, the p-values of the test in (1) performed on each
clique are shown in the first column. Among all the cli-
ques, nine cliques were found with different covariance
matrices in the two experimental conditions (p-values≤
0.1); the cliques are displayed in blue in Figure 6. The
test for differential expression repeated on each clique
gives 13 cliques as differentially expressed (p-values≤
0.1). The p-values are reported in the second column of
Table 1. Note that exact tests can be performed on cli-
ques with homogeneous covariances: the exact p-values
are highlighted in italics.
Interestingly, we found that only few cliques are char-
acterized by significant p-values in both tests, some
show only significant test (1) and some others signifi-
cant test (2). In particular, cliques resulted to be signifi-
cant by means of test (1) identify a clear path starting
from CD22 and CD72 and ending at AP1 (also known
as JUN, jun oncogene), going through RasGRP3, Ras,
Raf, MEK1/2 and ERK enzymes (both involved in the
MAPK signaling pathway, see Figure 1). The starting
and the ending point of this path is composed by cli-
ques with both tests significant. This path is in agree-
ment with the experimental findings about BCR/ABL
fusion gene consequences. In particular, expression of
BCR/ABL leads to activation of Ras. The events subse-
quent to Ras activation suggest an involvement of
MAPK and JNK pathways leading to an activation of
JUN [16,17].
On the other hand, cliques resulted to be significant
by means of test (2) seem to be more sparse along the
pathway. They identify the way in (CD72, CD22, SHP1)
and the three ways out, (NFAT, CaN), (ERK, AP1) and
(IKK, IKB, NFKB) of the pathway. These results are con-
cordant with recent findings that show the involvement
of NFAT and NFKB signaling in leukemia development.
Deregulation of calcineurin/NFAT signaling and/or
abnormal expression of its components, have recently
been reported in solid tumors of epithelial origin, lym-
phoma and lymphoid leukemia. In mouse models of
human T-ALL/lymphoma the persistent activation of
calcineurin/NFAT signaling is shown to be pro-onco-
genic, [18]. Moreover, NFKB is a transcription factor
that regulates genes involved in immune and inflamma-
tory responses, cell proliferation, and cell differentiation
and has recently been shown to be antiapoptotic. BCR/
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NFKB-dependent gene expression [19]. All these signal
cascades lead to cell proliferation, a biological process
that is known to be highly involved in tumor develop-
ment and progression.
We remark that, in testing the hypotheses on the cli-
ques, there is the possibility that some cliques will be
declared statistically different at some significance level,
even if the corresponding null hypotheses are true (type
I errors). Given the significance level for the tests, the
proportion of type I errors in the 30 test is difficult to
estimate, because the test statistics used to perform the
single tests are not independent, being functions of
overlapping sets of variables. With reference to the BCR
pathway, we studied this question via a simulation
study. For 1000 runs, we generated samples for the two
conditions (BCR-presence of rearrangement, NEG-
absence of rearrangement) from the same graphical
model ℳ(G)={ Y ~ N35(μ, Σ), Σ
-1 Î S
+(G)}, having the
undirected graph G associated to the BCR pathway.
Figure 3 DAG D obtained from BCR pathway. DAG D corresponding to the BCR signaling pathway.
Figure 4 DAG, moral graph, triangulated graph. Example of a DAG (A), the corresponding moral graph (B), and one possible triangulated
graph (C).
Massa et al. BMC Systems Biology 2010, 4:121
http://www.biomedcentral.com/1752-0509/4/121
Page 6 of 15Decomposition of such model clearly leads to the same
cliques previously studied; obviously, all the 30 hypoth-
eses relative to equality of the covariances (means) on
t h ec l i q u e sa r e ,i nt h i ss e t t i n g ,t r u eb yc o n s t r u c t i o n .A t
each run, we counted the number m,0≤ m ≤ 30, of
rejections (type I errors) observed in the 30 tests. The
distribution of m gives an indication on the proportion
of type I errors on the 30 cliques that one should
expect.
Different initial configurations, in terms of values of
the mean µ, of the covariance matrix Σ,a n do fs a m p l e
sizes, were tried. Here, we discuss the results for a set-
ting reproducing our experimental conditions. We set
n1 = 37 (BCR) and n2 = 41 (NEG), with an initial covar-
iance matrix Σ equal to the sample estimate of the
matrix in the NEG condition. Without loss of generality,
we fixed μ = 0. The mean number of cliques erro-
neously rejected was 1.5, and the proportion of cases
with more than nine rejections is 0.001, suggesting that
it is extremely rare observing a number of rejections
greater than the number that we have observed on our
experimental data when all the null hypotheses are true.
ERBB signaling pathway
The same analyses have been performed on a part of the
ERBB signaling pathway (see the corresponding DAG in
Figure 7). Firstly, we found that the test in (1) rejects
the null hypothesis (p-value =2 . 3×1 0
-8 ) for the moral
graph shown in Figure 8; thus the strength of the con-
nections among genes in this pathway is significantly
different between EGFR positive and negative mutated
samples. The test on the means reported in (2) rejects
Figure 5 Moral graph D
m obtained from BCR pathway. Moral graph D
m corresponding to the BCR signaling pathway.
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in agreement with the results derived from application
of the multivariate approaches of [2] (p-value =0 . 0 6 5 9 )
and of [8] (p-value = 0.0037).
After triangulation of the moral graph (see Figure 9),
the part of the EGFR pathway we considered is com-
posed by 23 cliques (as reported in Table 2), five cliques
as input, all coupling with EGFR gene, and three cliques
as output (JNK-Jun, JNK-Elk-ERK and ERK-Myc). The
test in (1) performed on each single clique identifies 11
cliques with significantly different covariance matrices
(p-value ≤ 0.05) in the two groups of patients. The cli-
ques are highlighted in Figure 9. The test for differential
expression gives only six cliques as differentially
expressed (p-value ≤ 0.05, see Table 2). As in the
previous case, only a small number of cliques show sig-
nificant p-values in both tests (1) and (2). According to
results of test (1) there are two clear signal paths in the
graph starting from EGFR gene following MAPK path-
way ending respectively to ERK and JNK. Both paths
lead to cell proliferation and differentiation, two key bio-
logical processes in cancer development. These results
are in agreement with experimental findings that show
how EGFR mutations result in activation of the antia-
poptotic pathways (PI3K/AKT and JAK-STAT), and in
cellular proliferation through ERK/MAPK signaling [20].
A simulation study similar to the one performed for the
BCR pathway has been conducted, showing that propor-
tion of cases in which more than 11 null hypotheses are
rejected is 0.001.
Figure 6 Triangulated graph D
t obtained from BCR pathway. Triangulated graph D
t corresponding to the BCR signaling pathway.
Massa et al. BMC Systems Biology 2010, 4:121
http://www.biomedcentral.com/1752-0509/4/121
Page 8 of 15Testing single vertices
It is worth studying also the significance of a clique in
relation to its individual members. It is not necessarily
true that all members of a significant clique are, indivi-
dually, statistically significant. Table 3 reports the q-
values [21] from the SAM test [13] performed on each
gene of the BCR signaling pathway. For example, the cli-
que (LYN, SYK, BTK, BLNK) has a significant p-value
but neither of the single genes has a significant q-value.
Table 4 reports the same quantities for each gene of the
ERBB signaling pathway. In this case, q-values associated
to ERBB pathway nodes show a moderate significance
(the lowest q-value is 0.09); this demonstrates how a
gene set approach using signaling pathways, and in
particular, our graphical approach is able to improve
microarray results interpretation.
As a general view, it seems that pathological condi-
tions are able to alter not only gene expression but also
the strength of the connection among genes. These
results partially change the idea that pathway edges are
static entities, moving towards the concept that links
among gene products modify their strength according to
the molecular modifications. Thus, in order to have an
overall idea of the pathway deregulation resulting from
the pathology investigated, we suggest that the complete
information derived from tests (1) and (2) should
be used, whenever gene sets analysis wants to be
performed.
Conclusions
Multivariate approaches proposed so far for gene sets
analysis test, through gene expression values, pathways
mean differences between groups. However, mean dif-
ferences are related to correlation differences among
genes within a gene set. Here, we propose two tests that
exploit the graphical evidence of a pathway, and allow
the decomposition of the pathway into components that
can be marginally compared. The first one is focussed
on the strength of the links among genes of a pathway
between two groups. The second test is the usual test
for differential expression, but in addition it contains
the information coming from the topology of the path-
way. This permits to evaluate in detail which compo-
nents of the pathway contribute at most in its
deregulation. It is worth noting that the components of
a biological pathway are not always regulated at the
level of expression, but at the level of proteins. There-
fore other types of data may be useful to detect changes
between proteins in a pathway.
Our approach is tested on gene expression data on i)
acute lymphocytic leukemia (ALL) with and without
BCR/ABL gene rearrangement and ii) lung adenocarci-
noma with and without EGFR mutation. In the first case
our approach identifies, as expected, the B cell receptor
pathway significantly involved in groups difference and
shows that only a part of the entire pathway seems to
be responsible of the different prognostic behaviour of
BCR/ABL positive and negative patients. In particular,
we find, in agreement with published experimental evi-
dences, that JUN oncogene with RAS/MAPK/JNK fol-
lowed by NFAT and NFKB seem to be the key
regulatory elements in the comparison of BCR/ABL
positive and negative patients.
In the second case, the EGFR pathway is found signifi-
cantly involved in the difference between lung cancer
patients with and without EGFR mutation. However,
w i t h i nE G F Rp a t h w a yw ef o u n ds i g n i f i c a n to n l yt w o
Table 1 Cliques of D
t with corresponding p-values for
BCR pathway
H0 : Σ1 = Σ2 H0 : μ1 = μ2
Clique p-value p-value
(PLCG2, SYK, BTK, BLNK) 0.056 0.122
(PLCG2, SYK, PI3K) 0.164 0.075
(PLCG2, CaN) 0.988 0.023
(PLCG2, SOS, BLNK) 0.570 0.008
(PLCG2, SOS, RaSGRP3) 0.715 0.013
(PLCG2, PKCB, BCL10) 0.942 0.002
(PLCG2, BCL10, PI3K) 0.796 0.059
(CD72, CD22, SHP1) 0.026 0.000
(LYN, SYK, BTK, BLNK) 0.008 0.549
(LYN, SYK, BTK, SHP1) 0.000 0.475
(LYN, CD79) 0.832 0.780
(LYN, CD19) 0.989 0.358
(LYN, VAV, BLNK) 0.920 0.696
(LYN, VAV, RAC) 0.336 0.141
(NFAT, CaN) 0.529 0.002
(GRB2, BLNK, SOS) 0.821 0.201
(Ras, RaSGRP3) 0.044 0.121
(Ras, Raf) 0.243 0.182
(Raf, MEK1/2) 0.101 0.825
(MEK1/2, ERK) 0.252 0.593
(ERK, AP1) 0.028 0.026
(IKK, BCL10, AKT) 0.430 0.524
(IKK, IKB, NFKB) 0.547 0.002
(AKT, PI3K, BCL10) 0.476 0.142
(AKT, PI3K, SHIP) 0.558 0.215
(AKT, GSK3B) 0.631 0.017
(CD81, SYK, PI3K) 0.395 0.193
(SHIP, FcgRIIB) 0.980 0.443
LEU13 0.103 0.003
CD21 0.008 0.008
Cliques of the triangulated graph D
t with corresponding p-values for the BCR
pathway. The first column refers to the test (1), the second one to the test (2).
The p-values in italics in the second column are exact, i.e., are computed on
the exact null distribution of the test statistics.
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tion and differentiation processes.
Pathway sizes are highly heterogeneous, there are
pathways characterized by complex structures, and,
then, composed by more than fifty gene products, and
other composed by less than ten gene products. From a
statistical point of view, inference results could be
affected by the size of the pathway. However, the idea of
focussing on components of a pathway may be particu-
larly useful also for the inference aspects of the n <p
cases. When the sample size is smaller than the number
of genes, i.e. n <p, and, in addition, n is smaller than the
dimension of the larger clique of the graph, a shrinkage
covariance matrix with null elements corresponding to
the missing edges of the graph G may be employed.
This is a modification of the approach proposed by [8],
where a shrinkage covariance matrix [22] is used as esti-
mate of the covariance matrix employed by the test. In
our context, the same shrinkage covariance matrix must
be used as input of the IPS algorithm. In this way, the
estimated covariance matrix is a covariance matrix of a
Gaussian graphical model with graph G.I fas h r i n k a g e
estimator for the covariance matrices is employed, per-
mutation methods have to be applied to derive an
approximation of the null distribution of the test statis-
tic -2 log Λ. Most of the time, researchers do not know
Figure 7 DAG D obtained from ERBB pathway. DAG D corresponding to the chosen portion of ERBB signaling pathway.
Figure 8 Moral graph D
m obtained from ERBB pathway. Moral graph D
m corresponding to the chosen portion of ERBB signaling pathway.
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Page 10 of 15which pathway to investigate in the first place. Or scien-
tists have an interest in many pathways, because most
conditions are the outcome of effects in more than one
pathway and some pathways may get affected more than
others. Just because a pathway changes moderately, it
would not necessarily mean that the condition is an out-
come of that. Which pathway(s) to focus upon is a very
critical decision that should be taken by experts on the
basis of the research questions. We remark that our
technique allows to check for differences on each of
such pathways, so that a global picture could be com-
posed by composition of the results on the individual
pathways.
Methods
Converting a pathway into a graphical model
Even if there is not a precise definition, a biological
pathway can be described as a set of linked biological
components interacting with each other over time to
generate a single biological effect. They comprise a myr-
iad of interactions, reactions, and regulations, which are
often identified piecemeal over extended periods and by
a variety of researchers. Moreover, participants in one
pathway can be involved also in others, leading to
dependent pathways. As a result, the pathway’s topology
has to be considered as a dynamic entity whose infor-
mation is particularly challenging to compile and orga-
nize. There are several valid and exhaustive pathway
repositories reporting pathway topologies as networks of
functional interactions such as KEGG [9], Biocarta,
Reactome [23] and WikiPathways [24].
Figure 9 Triangulated graph D
t obtained from ERBB pathway. Triangulated graph D
t corresponding to the chosen portion of ERBB signaling
pathway.
Table 2 Cliques of D
t with corresponding p-values for the
ERBB pathway
H0 : Σ1 = Σ2 H0 : μ1 = μ2
Clique p-value p-value
(EGFR, EGF, TGFA, AR, BTC, EPR) 0.245 0.147
(EGFR, PLCG) 0.233 0.006
(EGFR, Cbl) 0.004 0.007
(EGFR, STAT5) 0.141 0.318
(EGFR, Src) 0.224 0.176
(EGFR, Crk) 0.047 0.196
(EGFR, Nck, Grb2) 0.018 0.104
(EGFR, Shc, Grb2) 0.390 0.159
(Sos, Grb2, Ras) 0.031 0.145
(Ras, MEK, Raf) 0.022 0.030
(Ras, MEK, JNKK) 0.004 0.694
(Ras, Grb2, JNKK) 0.048 0.757
(MEK, JNK, JNKK) 0.009 0.186
(MEK, JNK, ERK) 0.678 0.075
(ERK, JNK, Elk) 0.125 0.242
(ERK, Myc) 0.515 0.101
(Src, FAK) 0.421 0.524
(Crk, Abl) 0.000 0.135
(PAK, Nck, JNKK) 0.004 0.099
(JNKK, Nck, Grb2) 0.011 0.190
(JNK, Jun) 0.559 0.033
(PLCG, CAMK) 0.930 0.012
(PLCG, PKC) 0.127 0.048
Cliques of the triangulated graph D
t with corresponding p-values for the ERBB
pathway. The first column p-values refers to the test (1), the second one to
the test (2). The p-values in italics in the second column are exact, i.e., are
computed on the exact null distribution of the test statistics.
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Page 11 of 15In this study, we use KEGG maps, as they represent a
good compromise between map accurateness and sim-
plicity. Nevertheless, it is important to note that our
approach can be used whichever is the origin of the
map. KEGG [9] is one of the mostly used pathways
databases, with more than a hundred of pathways and
more than fifty available signaling pathways. Figure 1
represents an example of such pathways, the B cell
receptor signaling pathway in human. It is composed by
edges and nodes, which have the following meanings.
Rectangles represent gene products, mostly proteins, but
also RNA and complexes. The edges between rectangles
represent functional interactions and they can be
undirected, directed, directed with a +p, directed with a
-p, dashed and directed, directed with a bar at the end.
Circles are other types of molecules, mostly chemical
compounds, while the large white rectangles are the
links to other pathways. See the KEGG website for a
more detailed description and meaning of the different
types of edges and circles.
We refer the reader to the Appendix for an essential
lexicon on graphical models. To keep track of the initial
structure of the genes, we convert the structure of a
pathway into a directed acyclic graph (DAG) D,b yf o l -
lowing these simple steps: i) inhibition, phosphorylation
(+p) and dephosphorylation (-p) are considered as sim-
ple directed edges; ii) undirected edges are directionated
using additional information derived by Biocarta path-
way and iv) in case of complexes (nodes composed by
multiple gene products) we consider as expression of
the complex the first principal component. This is a lin-
ear combination of gene expression values of all gene
Table 3 q-values from SAM analysis for each gene of the
BCR pathway
Gene q-value
CD22 0.00
CD72 0.00
SHP1 0.17
SYK 0.41
CD79 0.55
LYN 0.41
BTK 0.17
BLNK 0.50
VAV 0.50
RAC 0.13
PLCG2 0.09
CaN 0.00
NFAT 0.00
GRB2 0.41
SOS 0.00
RaSGRP3 0.44
Ras 0.17
Raf 0.50
MEK1/2 0.41
ERK 0.50
AP1 0.00
PKCB 0.05
BCL10 0.55
IKK 0.55
IKB 0.00
NFKB 0.00
FcgRIIB 0.41
SHIP 0.29
PI3K 0.00
AKT 0.17
GSK3B 0.00
CD19 0.09
CD21 0.00
CD81 0.41
LEU13 0.00
Genes of the BCR signaling pathway with corresponding q-values [21] from
SAM analysis [13].
Table 4 q-values from SAM analysis for each gene of the
ERBB pathway
Gene q-value
EGF 0.29
TGFA 0.09
AR 0.09
BTC 0.09
EPR 0.09
EGFR 0.22
PLCG 0.09
Cbl 0.09
STAT5 0.20
Src 0.20
Crk 0.24
Nck 0.09
CAMK 0.24
PKC 0.29
FAK 0.23
Abl 0.09
PAK 0.09
JNKK 0.20
JNK 0.09
Jun 0.09
Elk 0.16
Shc 0.09
Grb2 0.20
Sos 0.09
Ras 0.13
Raf 0.11
MEK 0.16
ERK 0.22
Myc 0.09
Genes of the ERBB signaling pathway with corresponding q-values [21] from
SAM analysis [13].
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Page 12 of 15products in the same complex which retains most of the
variation in the dataset.
Then, we convert D into a moral graph, D
m, by adding
edges between the parents of each vertex (if not already
present), and, then, by removing the directionality of the
original edges (see the Appendix). Usually, D
m has more
edges than D,b u tt h ec h o i c eo fw o r k i n gw i t ham o r a l
graph does not affect the purpose of this study. We
assume to model the data of the same pathway in differ-
ent experimental conditions as realizations of undirected
graphical Gaussian models [15] sharing the same undir-
ected graph G given by the moral graph D
m.T oe x e m -
plify, in the case of two conditions, we assume the
Gaussian models


11 1 1
1
22 2 2
1
() { ~ ( , ) , () } ,
() { ~ ( , ) , (
GY N S G
GY N S
p
p
=∈
=∈
−+
−+


ΣΣ
ΣΣ G G)}.
Here, p is the number of genes (vertices of the graph)
and S
+(G) is the set of symmetric positive definite
matrices with null elements corresponding to the miss-
ing edges of G. Note that the assumption of normality
of the data is motivated by the well known fact that
relative or absolute gene expression measurements are
approximately normal on the log scale.
Of course, in real applications, the parameters of the
m o d e l s ,i . e .t h em e a n sμ1 and μ2 and the covariance
matrices Σ1 and Σ2 are not known, although the position
of zeros elements in the concentration matrices Σ1
1 −
and Σ2
1 − is defined by the graph. Therefore, they need
to be estimated from the data. The estimates of the cov-
ariance matrices can be obtained by running the Itera-
tive Proportional Scaling algorithm (IPS in the
following, see [15]) on the sample covariance matrices,
which guarantees that the estimated matrices are posi-
tive definite and their inverse have null elements corre-
sponding to the missing edges of the graph. The sample
covariance matrices can be computed by selecting the
expression levels of the genes on the pathway and by
computing the sample covariances. The same matrices
can be obtained from the chip covariance matrices by
extracting the elements corresponding to all the pairs of
genes in the pathway.
Comparing gene sets
Adopting the graphical arguments, the assessment of
whether the expression of a pathway changes in differ-
ent experimental conditions fits naturally within the fra-
mework of testing hypothesis on the graphical models.
The process of identifying the null hypotheses to be
tested is now particularly simple.
Several potential reasons may exist inducing differ-
ences in the global expression of the pathway.
A possibility is that the expression changes because the
strength of the relations defining the pathway change in
different conditions. As information on the relations is
stored into the covariance matrices of the graphical
models, such hypothesis corresponds to the hypothesis
of homogeneity of the covariance matrices. Moreover,
the mean expression may change, irrespective to what
happens to the correlations among genes. The corre-
sponding hypothesis is that of equality of two means.
Despite the deceiving simplicity of this hypothesis, its
assessment is not trivial and depends on whether the
covariances of the models, generally unknown, are
homogeneous or not. Therefore, an appropriate analysis
of the means depends on the decision taken on the
homogeneity hypothesis. In what follows, we will
describe such tests, following the ideal sequence in
which we think that they should be performed on real
data. It is worth noting that normal distributions are
fully characterized by the first two orders of moments.
Therefore, tests covering the first two moments fully
exploit the distributions’ characteristics. We will assume
to have two experimental conditions.
Testing equality of the strength of the relations among
genes
We are interested in comparing the strength of the links
between genes in two experimental conditions. In a gra-
phical Gaussian models context this is simply achieved
by comparing the two concentration matrices (inverse
of the covariance matrices), because they contain all the
information about the underlying structure. Therefore,
the interest is in testing the hypothesis ΣΣ 1
1
2
1 −− = .
The following methodology is the transposition of the
methods for comparing covariance matrices [25] to the
specific case of graphical Gaussian models.
Without loss of generality, suppose to have yy
j
11 = () ,
j = 1, ..., nl observations from Np(0, Σ1)a n dyy
j
22 = () ,
j = 1,..., n2 observations from Np(0, Σ2), with
Σ1
1
1
−+ =∈ KS G ()and Σ2
1
2
−+ =∈ KS G () .
We want to test the hypothesis
HK K HK K 01 2 11 2 :: . =≠ against (1)
If we set Wy y i i
j
j
n
i
j T i =
= ∑ () ()
1 , i =1 ,2 ,t h el i k e l i h o o d
function, L(K1, K2)i s
LK K
nip
K
ni
e
i
i
KW ii
(, ) () ( d e t) ,
()
12
1
2
2 22
1
2 =
−
=
−
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tr
and each block of it may be maximized separately
[25]. In more detail, the estimates K
^
1 and K
^
2 are
computed by direct calculation (if the graph is decom-
posable) or, in general, by using the IPS algorithm, see
[15]. Under the null hypothesis, the algorithm computes
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Page 13 of 15the estimate, Σ
^ , of the common covariance matrix Σ
starting from the pooled covariance matrix
Snn n S n S =+ − − ⋅ +− ⋅ ⋅
− () { ( ) ( ) } . 12
1
11 22 21 1
Under the alternative hypothesis, the algorithm com-
putes ˆ Σ1 and ˆ Σ2 using the sample covariance matrices
Sn W Sn W 11
1
12 2
1
2 11 =− =− ⋅⋅
−− () () . and
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1. The likeli-
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If we let W = W1 + W2, and exploit the fact that
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(see [15]), we have
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The asymptotic null distribution of -2 log Λ is rp +
2 ,
where r is the number of edges of G.T h ea b o v eg i v e n
test might suffer of a weakness. It is well known from
the literature that the likelihood ratio test for the equal-
ity of two covariance matrices is not particularly robust
to violations of the normality assumption. If this is the
case, several robust variants of the above given test
could be defined following the developments already
available in the literature. For example, one could follow
[26], who proposes several Wald tests for elliptical and
non-normal distributions.
If the test rejects the null hypothesis, the graphical
approach allows us to look for the sources of differences
of the two concentration matrices. In fact, if the graph
is decomposable, it is possible to decompose it into its
maximal complete subgraphs (cliques) and repeat the
previous test for each clique. In this way, the maximum
likelihood estimate of the sub-covariance matrix for the
variables belonging to the same clique is directly per-
formed with the available data on the cliques and there
is no need of any marginalization. The test of equality
of the covariance matrices on the cliques can be tested
by following the standard methods (see [25]) without
need of using the results described at the beginning of
this section. Note that, in this way, the cliques are com-
pared only marginally. If the graph is not decomposable,
it is always possible to add extra edges in order to
obtain a new graph that is triangulated and therefore
decomposable (see the Appendix for more details). The
test can then be performed on the cliques of this graph.
Testing for differential expression
If the null hypothesis in (1) is not rejected, the differen-
tial expression of the pathway is tested by the hypothesis
H01 2 1 2 :.  == subject to ΣΣ
This test can be performed by using exact procedures
such as a multivariate analysis of variance (MANOVA),
as, for example, in [8]. Otherwise, if we reject the null
hypothesis of homogeneity in (1), the hypothesis to be
tested is
H01 2 1 2 :.  =≠ subject to ΣΣ (2)
This is the usual test for equality of means in a two
sample problem with unequal covariance matrices, also
called Behrens-Fisher problem (see [25]).
In both cases, the standard tests are to be opportunely
adjusted in order to consider that the data come from
Gaussian graphical models, and, therefore, have a struc-
tured covariance matrix. This, clearly, involves a con-
strained estimation of the covariance matrices, carried
out, for example, with the IPS algorithm.
Appendix
In this section, we concisely collect some definitions
about graphs and their properties that are useful for
reading the paper. For more details, see [15].
Ag r a p hG is a pair G =( V, E), where V is a finite set
of vertices and the set of edges E ⊆ V×V is the set of
ordered pairs of distinct vertices. If both (u, v) Î E and
(u, v) Î E, the edge (u, v) is said to be undirected. If (u,
v) Î E but (u, v) ∉ E,t h ee d g e( v, u)i ss a i dt ob e
directed.
If the graph has only undirected edges, it is called
undirected, whereas if all the edges are directed, it is
called directed. In an undirected graph, if there is an
edge between u and v, u and v are said to be adjacent.
In a directed graph, if u ® v, u is said to be a parent of
v and v a child of u.
A path is a sequence of vertices such that every vertex
has an edge to the next vertex in the sequence. A cycle
is a path such that the first vertex of the path corre-
sponds to the last one.
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Page 14 of 15A directed acyclic graph (DAG) is a directed graph
without cycles. Given a DAG D, a moral graph D
m is
the undirected graph obtained from D by adding undir-
ected edges between all pairs of vertices that have a
child in common (if they are not already present) and
then by rendering all edges undirected.
A graph is complete if E contains all pairs of distinct
elements of V. GA =( A, EA) is a subgraph of G =( V, E)
if A ⊆ V and EA = E ⋂ (A×A). A complete subgraph that
is not contained within another complete subgraph is a
clique.
At r i p l e( A, B, C) of disjoint subsets of V of an undir-
ected graph G is a decomposition of G if V = A ⋃ B ⋃
C, C is a complete subset of V and C separates A and B.
An undirected graph is decomposable if either it is com-
plete or it possesses a proper decomposition (A, B, C)
such that both subgraphs GA⋃B and GB⋃C are
decomposable.
A triangulated graph (also called chordal graph) is an
undirected graph with the property that every cycle of
length n ≥ 4 has two non-consecutive vertices that are
adjacent.
An important result is that an undirected graph is
decomposable if and only if it is triangulated, see [15].
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